MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities

Core Insights - Renalytix Plc and MVP Health Care have formed a partnership to enhance access to kidney care for individuals with type 2 diabetes and chronic kidney disease, aiming to improve health outcomes and reduce health disparities [1][2] - The collaboration will implement the kidneyintelX.dkd™ FDA-approved test across MVP's network, facilitating earlier interventions and personalized care plans for patients [2][3] - The kidneyintelX.dkd™ test will be available to all MVP customers in New York, including those with Medicare or Medicaid, and is endorsed by KDIGO, the international clinical guideline organization for kidney disease [3] Company Overview - Renalytix is an AI-enabled in vitro diagnostics company focused on improving clinical management of kidney disease, with FDA approval and Medicare reimbursement for the kidneyintelX.dkd test [5] - MVP Health Care is a not-for-profit health insurer serving New York and Vermont, dedicated to enhancing the well-being of its members and communities [6] Impact on Patient Care - The partnership aims to identify patients at higher risk for kidney function decline earlier, allowing for targeted resources and therapeutic options, which can lead to better management of cardiovascular and metabolic conditions [1][4] - The use of kidneyintelX.dkd has shown measurable improvements in patient outcomes and quality metrics, particularly in managing blood pressure and HbA1c levels in high-risk populations [4]